ASLAN Pharmaceuticals Limited, one of our portfolio companies, has been listed on Taipei Exchange.


The founding of a new biotech company「J-mab Therapeutics, Inc.」


The Fund Size increased to JPY 11.6 Billion


DCI Partners will give a speech scheduled on July 22th in Bio Taiwan 2015

  Visit http://bio-taiwan.com/en for more information.


Establishment of Daiwa Taiwan-Japan Biotech Fund Investment Limited Partnership

Company Name DCI Partners Co., Ltd.
Head Office
GranTokyo North Tower 1-9-1, Marunouchi, Chiyoda-ku,Tokyo  [MAP]
TEL  +81-3-5555-6336  /  E-mail  dcip_info@daiwa.co.jp
Establishment May 20, 2014
Share Capital 50 million yen
Business Description Management of venture capital funds specialized in the life science field
Fund under management: Daiwa Taiwan-Japan Biotech Fund
Fund Size JPY 11.6 Billion
Board of Directors
Hiroki Narita President & CEO
Hisaharu Momoshima Compliance Officer
Shuntaro Kodama Managing Director
Kinya Kuramoto Audit & Supervisory Board Member

・ Biotech Start-ups centered on the therapeutic field in Japan and Taiwan
・ Spin-out or carve-out opportunities from pharmaceutical / biopharmaceutical
    companies and academia